Tolazamide

Overview

Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 ( SUR1 ) linked to the inwardly rectifying potassium channel ( IC 50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Endocrinology | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Potassium Channel

Product Information

• Catalog No.: HY-B0920
• CAS No.: 1156-19-0
• Molecular Formula: C14H21N3O3S
• Molecular Weight: 311.40
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source